8-K current report · filed Aug 4, 2026

Pfizer Inc (PFE) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02PFE overview

Short answer

Pfizer Inc (PFE) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Pfizer announced financial results for the second quarter of 2026.

Pfizer Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Pfizer announced financial results for the second quarter of 2026
  • Exhibit 99 contains the detailed earnings release and operating results

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $15.034B, up 3%; operational growth 1%, excluding Comirnaty and Paxlovid growth reached 5%
  • Launched and acquired products grew 18% operationally, led by Eliquis 19%, Padcev 23%, Vyndaqel 8%, and Lorbrena 37%
  • Adjusted EPS $0.77; reported loss $(0.04) reflects $4.3B of non-cash intangible impairments
  • 2026 revenue guidance raised to $60.5B–$62.5B, midpoint up $500M; COVID revenue expectation reduced to approximately $4B
  • Additional savings targeted: $2.5B through 2029, requiring approximately $6.0B in one-time costs across productivity and manufacturing programs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pfizer Inc 8-K filings

Get the next PFE 8-K as it lands

Follow PFE for push alerts, or ask the research agent what this filing means.